+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Filgrastim Market by Drug Type, Indication, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • ID: 5521597
  • Report
  • October 2021
  • Region: Global
  • 193 Pages
  • Allied Analytics LLP

FEATURED COMPANIES

  • Abbott Laboratories
  • Amgen
  • Apotex
  • Cadila Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Novartis
The global filgrastim market was valued at $ 562.50 million in 2020 and is projected to reach $ 745.90 million by 2030 registering a CAGR of 2.80% from 2021 to 2030.

Filgrastim is a drug that is used to increase the production of granulocytes (a type of white blood cell) in patients who are receiving treatment that causes low white blood cell counts. Filgrastim is used to prevent infection and neutropenic (low white blood cells) fevers caused by chemotherapy. Filgrastim is a support medication used in this therapy. Filgrastim injection is also used to increase the chance of survival in people who have been exposed to harmful amounts of radiation, which can cause severe and life-threatening damage to bone marrow. Furthermore, filgrastim is in a class of medications called colony-stimulating factors. It aids the body's production of neutrophils. On the other hand, common adverse effects of filgrastim include joint pain, chest pain, hair loss, and vomiting.

Factors such as increase in prevalence of various diseases and surge in geriatric population, drive the filgrastim market growth. Furthermore, increase in pressure to decrease healthcare expenditure and surge in demand for filgrastim due to its cost effectiveness is anticipated to boost the growth of this market. In addition, surge in demand for biosimilars in the treatment of neutropenia further impede the market growth. However, common adverse effects of filgrastim include joint pain, chest pain, hair loss, and vomiting hinder the market growth. Conversely, increase in investing extensively in R&D activities for the development of effective and innovative biosimilars will further provide opportunities for the market.

The global filgrastim market segmented on the basis of drug type, distribution channel, indication and region. On the basis of drug type, it is further classified into biologic and biosimilar. By distribution channel, it is divided into hospital pharmacies, retail pharmacies and online pharmacies. Based on indication, it is categorized into chemotherapy induced netropenia, chronic neutropenia and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global filgrastim market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps understand the drug types of filgrastim market used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS


By Drug Type

  • Biologic
  • Biosimilar

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Indication

  • Chemotherapy induced Netropenia
  • Chronic Neutropenia
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • Abbott Laboratories
  • Amgen
  • Apotex
  • Cadila Pharmaceuticals
  • Dr. Reddy's Laboratories "
  • Kirin Holding (Kyowa Kirin)
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries Ltd
  • Toksöz Group (Arven)
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Amgen
  • Apotex
  • Cadila Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Novartis

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Surge in geriatric population
3.5.1.2. Rise in demand for biosimilars in the treatment of neutropenia
3.5.1.3. Pharmaceutical companies are shifting toward biosimilar drug development
3.5.2. Restraints
3.5.2.1. Complexities in manufacturing of biosimilar
3.5.2.2. Increase in use of pegfilgrastim biologic
3.5.3. Opportunities
3.5.3.1. Increase in player-adopted strategies
3.5.3.2. Increase in awareness related to filgrastim
3.5.4. Impact analysis
3.6. COVID-19 Impact analysis on the filgrastim market
CHAPTER 4: FILGRASTIM MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Biologic
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.2.1. Market size and forecast for biologic by distribution channel
4.2.3. Market analysis, by country
4.3. Biosimilar
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.2.1. Market size and forecast for biosimilar by distribution channel
4.3.3. Market analysis, by country
CHAPTER 5: FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital pharmacies
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Retail pharmacies
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Online pharmacies
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
CHAPTER 6: FILGRASTIM MARKET, BY INDICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Chemotherapy induced Netropenia
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Chronic neutropenia
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Others
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: FILGRASTIM MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S. filgrastim market
7.2.2.2. U.S. filgrastim market, by drug type
7.2.2.3. U.S. filgrastim market, by distribution channel
7.2.2.4. U.S. filgrastim market, by indication
7.2.2.5. Canada filgrastim market
7.2.2.6. Canada filgrastim market, by drug type
7.2.2.7. Canada filgrastim market, by distribution channel
7.2.2.8. Canada filgrastim market, by indication
7.2.2.9. Mexico filgrastim market
7.2.2.10. Mexico filgrastim market, by drug type
7.2.2.11. Mexico filgrastim market, by distribution channel
7.2.2.12. Mexico filgrastim market, by indication
7.2.3. North America market size and forecast, by drug type
7.2.4. North America market size and forecast, by distribution channel
7.2.5. North America market size and forecast, by indication
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany filgrastim market
7.3.2.2. Germany filgrastim market, by drug type
7.3.2.3. Germany filgrastim market, by distribution channel
7.3.2.4. Germany filgrastim market, by indication
7.3.2.5. France filgrastim market
7.3.2.6. France filgrastim market, by drug type
7.3.2.7. France filgrastim market, by distribution channel
7.3.2.8. France filgrastim market, by indication
7.3.2.9. UK filgrastim market
7.3.2.10. UK filgrastim market, by drug type
7.3.2.11. UK filgrastim market, by distribution channel
7.3.2.12. UK filgrastim market, by indication
7.3.2.13. Italy filgrastim market
7.3.2.14. Italy filgrastim market, by drug type
7.3.2.15. Italy filgrastim market, by distribution channel
7.3.2.16. Italy filgrastim market, by indication
7.3.2.17. Spain filgrastim market
7.3.2.18. Spain filgrastim market, by drug type
7.3.2.19. Spain filgrastim market, by distribution channel
7.3.2.20. Spain filgrastim market, by indication
7.3.2.21. Rest of Europe filgrastim market
7.3.2.22. Rest of Europe filgrastim market, by drug type
7.3.2.23. Rest of Europe Filgrastim market, by distribution channel
7.3.2.24. Rest of Europe Filgrastim market, by indication
7.3.3. Europe market size and forecast, by drug type
7.3.4. Europe market size and forecast, by distribution channel
7.3.5. Europe market size and forecast, by indication
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan Filgrastim market
7.4.2.2. Japan Filgrastim market, by drug type
7.4.2.3. Japan Filgrastim market, by distribution channel
7.4.2.4. Japan Filgrastim market, by indication
7.4.2.5. China Filgrastim market
7.4.2.6. China Filgrastim market, by drug type
7.4.2.7. China filgrastim market, by distribution channel
7.4.2.8. China filgrastim market, by indication
7.4.2.9. Australia filgrastim market
7.4.2.10. Australia filgrastim market, by drug type
7.4.2.11. Australia filgrastim market, by distribution channel
7.4.2.12. Australia filgrastim market, by indication
7.4.2.13. India filgrastim market
7.4.2.14. India filgrastim market, by drug type
7.4.2.15. India filgrastim market, by distribution channel
7.4.2.16. India filgrastim market, by indication
7.4.2.17. South Korea filgrastim market
7.4.2.18. South Korea filgrastim market, by drug type
7.4.2.19. South Korea filgrastim market, by distribution channel
7.4.2.20. South Korea filgrastim market, by indication
7.4.2.21. Rest of Asia-Pacific filgrastim market
7.4.2.22. Rest of Asia-Pacific filgrastim market, by drug type
7.4.2.23. Rest of Asia-Pacific filgrastim market, by distribution channel
7.4.2.24. Rest of Asia-Pacific filgrastim market, by indication
7.4.3. Asia-Pacific market size and forecast, by drug type
7.4.4. Asia-Pacific market size and forecast, by distribution channel
7.4.5. Asia-Pacific market size and forecast, by indication
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil filgrastim market
7.5.2.2. Brazil filgrastim market, by drug type
7.5.2.3. Brazil filgrastim market, by distribution channel
7.5.2.4. Brazil filgrastim market, by indication
7.5.2.5. Saudi Arabia filgrastim market
7.5.2.6. Saudi Arabia filgrastim market, by drug type
7.5.2.7. Saudi Arabia filgrastim market, by distribution channel
7.5.2.8. Saudi Arabia filgrastim market, by indication
7.5.2.9. South Africa filgrastim market
7.5.2.10. South Africa filgrastim market, by drug type
7.5.2.11. South Africa filgrastim market, by distribution channel
7.5.2.12. South Africa filgrastim market, by indication
7.5.2.13. Rest of LAMEA filgrastim market
7.5.2.14. Rest of LAMEA filgrastim market, by drug type
7.5.2.15. Rest of LAMEA filgrastim market, by distribution channel
7.5.2.16. Rest of LAMEA filgrastim market, by indication
7.5.3. LAMEA market size and forecast, by drug type
7.5.4. LAMEA market size and forecast, by distribution channel
7.5.5. LAMEA market size and forecast, by indication
CHAPTER 8: COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. AMGEN INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. APOTEX INC.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.4. DR. REDDY’S LABORATORIES LIMITED
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. KIRIN HOLDINGS
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. NOVARTIS AG
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Novartis offers the following products:
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. PFIZER INC.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. TOKSÖZ GROUP.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.10. ZYDUS CADILLA
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
List of Tables
TABLE 01. FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 02. FILGRASTIM MARKET FOR BIOLOGIC, BY REGION, 2020-2030 ($MILLION)
TABLE 03. BIOLOGIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 04. FILGRASTIM MARKET FOR BIOSIMILAR, BY REGION, 2020-2030 ($MILLION)
TABLE 05. BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 06. FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 07. FILGRASTIM MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2020-2030($MILLION)
TABLE 08. FILGRASTIM MARKET FOR RETAIL PHARMACIES, BY REGION, 2020-2030($MILLION)
TABLE 09. FILGRATIM MARKET FOR ONLINE PHARMACIES, BY REGION, 2020-2030($MILLION)
TABLE 10. FILGRASTIM MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 11. FILGRASTIM MARKET FOR CHEMOTHERAPY INDUCED NETROPENIA, BY REGION, 2020-2030 ($MILLION)
TABLE 12. FILGRASTIM MARKET FOR CHRONIC NEUTROPENIA, BY REGION, 2020-2030 ($MILLION)
TABLE 13. FILGRASTIM MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 14. FILGRASTIM MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 15. NORTH AMERICA FILGRASTIM MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 16. U.S. FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 17. U.S. FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 18. U.S. FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 19. CANADA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 20. CANADA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 21. CANADA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 22. MEXICO FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 23. MEXICO FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 24. MEXICO FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 25. NORTH AMERICA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 26. NORTH AMERICA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 27. NORTH AMERICA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 28. EUROPE FILGRASTIM MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 29. GERMANY FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 30. GERMANY FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 31. GERMANY FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 32. FRANCE FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 33. FRANCE FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 34. FRANCE FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 35. UK FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 36. UK FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 37. UK FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 38. ITALY FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 39. ITALY FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 40. ITALY FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 41. SPAIN FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 42. SPAIN FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 43. SPAIN FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 44. REST OF EUROPE FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 45. REST OF EUROPE FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 46. REST OF EUROPE FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 47. EUROPE FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 48. EUROPE FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 49. EUROPE FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 50. ASIA-PACIFIC FILGRASTIM MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 51. JAPAN FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 52. JAPAN FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 53. JAPAN FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 54. CHINA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 55. CHINA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 56. CHINA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 57. AUSTRALIA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 58. AUSTRALIA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 59. AUSTRALIA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 60. INDIA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 61. INDIA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 62. INDIA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 63. SOUTH KOREA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 64. SOUTH KOREA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 65. SOUTH KOREAFILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 66. REST OF ASIA-PACIFIC FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 67. REST OF ASIA-PACIFIC FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 68. REST OF ASIA-PACIFIC FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 69. ASIA-PACIFIC FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 70. ASIA-PACIFIC FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 71. ASIA-PACIFIC FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 72. LAMEA FILGRASTIM MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 73. BRAZIL FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 74. BRAZIL FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 75. BRAZIL FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 76. SAUDI ARABIA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 77. SAUDI ARABIA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 78. SAUDI ARABIA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 79. SOUTH AFRICA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 80. SOUTH AFRICA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 81. SOUTH AFRICA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 82. REST OF LAMEA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 83. REST OF LAMEA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 84. REST OF LAMEA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 85. LAMEA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 86. LAMEA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 87. LAMEA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 88. ABBOTT: COMPANY SNAPSHOT
TABLE 89. ABBOTT: OPERATING SEGMENTS
TABLE 90. ABBOTT: PRODUCT PORTFOLIO
TABLE 91. AMGEN: COMPANY SNAPSHOT
TABLE 92. AMGEN: OPERATING SEGMENT
TABLE 93. AMGEN: PRODUCT PORTFOLIO
TABLE 94. APOTEX: COMPANY SNAPSHOT
TABLE 95. APOTEX: OPERATING SEGMENTS
TABLE 96. APOTEX: PRODUCT PORTFOLIO
TABLE 97. REDDY: COMPANY SNAPSHOT
TABLE 98. REDDY: OPERATING BUSINESS SEGMENTS
TABLE 99. REDDY: PRODUCT PORTFOLIO
TABLE 100. KIRIN: COMPANY SNAPSHOT
TABLE 101. KIRIN: PRODUCT SEGMENTS
TABLE 102. KIRIN: PRODUCT PORTFOLIO
TABLE 103. NOVARTIS: COMPANY SNAPSHOT
TABLE 104. NOVARTIS: OPERATING SEGMENTS
TABLE 105. NOVARTIS: PRODUCT PORTFOLIO
TABLE 106. NOVARTIS: KEY DEVELOPMENTS
TABLE 107. PFIZER: COMPANY SNAPSHOT
TABLE 108. PFIZER: OPERATING SEGMENTS
TABLE 109. PFIZER: PRODUCT PORTFOLIO
TABLE 110. TEVA: COMPANY SNAPSHOT
TABLE 111. TEVA: OPERATING SEGMENTS
TABLE 112. TEVA: PRODUCT PORTFOLIO
TABLE 113. TOKSÖZ: COMPANY SNAPSHOT
TABLE 114. TOKSÖZ: OPERATING SEGMENTS
TABLE 115. TOKSÖZ: PRODUCT PORTFOLIO
TABLE 116. ZYDUS: COMPANY SNAPSHOT
TABLE 117. ZYDUS: OPERATING SEGMENTS
TABLE 118. ZYDUS: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. FILGRASTIM MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04. MODERATE BARGAINING POWER OF BUYERS
FIGURE 05. MODERATE THREAT OF SUBSTITUTES
FIGURE 06. HIGH THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE INTENSITY OF RIVALRY
FIGURE 08. TOP PLAYER POSITIONING, 2020
FIGURE 09. IMPACT ANALYSIS
FIGURE 10. COMPARATIVE ANALYSIS OF FILGRASTIM MARKET FOR BIOLOGIC, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF FILGRASTIM MARKET FOR BIOSIMILAR, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF FILGRASTIM MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF FILGRASTIM MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF FILGRATIM MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF FILGRASTIM MARKET FOR CHEMOTHERAPY INDUCED NETROPENIA, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF FILGRASTIM MARKET FOR CHRONIC NEUTROPENIA, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF FILGRASTIM MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18. ABBOTT: NET SALES, 2018-2020 ($MILLION)
FIGURE 19. ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 20. ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 21. AMGEN: NET SALES, 2018-2020 ($MILLION)
FIGURE 22. AMGEN: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 23. REDDY: NET SALES, 2019-2021 ($MILLION)
FIGURE 24. REDDY: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 25. REDDY: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 26. KIRIN: NET SALES, 2018-2020 ($MILLION)
FIGURE 27. KIRIN: REVENUE SHARE BY SEGMENT, 2020(%)
FIGURE 28. NOVARTIS: NET SALES, 2018-2020 ($MILLION)
FIGURE 29. NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30. NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 31. PFIZER NET SALES, 2019-2020 ($MILLION)
FIGURE 32. PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 33. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 34. TEVA: NET SALES, 2018-2020 ($MILLION)
FIGURE 35. TEVA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36. TEVA: REVENUE SHARE BY REGION, 2020(%)
FIGURE 37. ZYDUS NET SALES, 2019-2020 ($MILLION)
FIGURE 38. ZYDUS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39. ZYDUS: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Amgen
  • Apotex
  • Cadila Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Kirin Holding (Kyowa Kirin)
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries Ltd.
  • Toksöz Group (Arven)
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...